Search
Now showing items 11-20 of 184
Clinical and co-clinical genomics of paediatric solid tumours with a special focus in DIPG
(Institute of Cancer Research (University Of London), 2020-07-31)
Cure rates for paediatric solid cancers have not improved in the last decade. Delivering precision medicine to stratify patients based on their molecular profiling is a key goal to support existing and upcoming adaptive ...
Targeting androgen receptor splicing in lethal prostate cancer
(Institute of Cancer Research (University Of London), 2021-04-30)
Over the past decade, androgen receptor (AR) directed therapies such as abiraterone and enzalutamide have become the standard of care for treating advanced prostate cancer, improving both progression-free and overall ...
MAP4K4 Inhibitors
(2020-06-11)
This invention relates to compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these compounds, for example in a method ...
MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma.
(Impact Journals, LLC, 2020-06-09)
This study investigates the influence expression of the MYCN oncogene has on the DNA damage response, replication fork progression and sensitivity to PARP inhibition in neuroblastoma. In a panel of neuroblastoma cell lines, ...
Therapeutic vulnerabilities in the DNA damage response for the treatment of ATRX mutant neuroblastoma.
(ELSEVIER, 2020-09-01)
BACKGROUND: In neuroblastoma, genetic alterations in ATRX, define a distinct poor outcome patient subgroup. Despite the need for new therapies, there is a lack of available models and a dearth of pre-clinical research. ...
Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors.
(AMER SOC CLINICAL ONCOLOGY, 2020-06-22)
PURPOSE: Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging ...
canSAR: update to the cancer translational research and drug discovery knowledgebase.
(OXFORD UNIV PRESS, 2021-01-08)
canSAR (http://cansar.icr.ac.uk) is the largest, public, freely available, integrative translational research and drug discovery knowledgebase for oncology. canSAR integrates vast multidisciplinary data from across genomic, ...
Investigating acute cellular responses to elevated APOBEC3B expression
(Institute of Cancer Research (University Of London), 2021-09-30)
The cytosine deaminase APOBEC3B (A3B) functions as part of innate immunity by mutating viral DNA and preventing replication. Large-scale genome sequencing studies and examination of expression levels have identified mutations ...
Precision genomics for prostate cancer patient stratification
(Institute of Cancer Research (University Of London), 2020-10-31)
Introduction Several unmet needs currently persist in advanced prostate cancers. Despite recent discoveries, such as identification of deficient DNA repair pathways as a key driver of prostate tumour development, relatively ...
Characterizing the metabolic fate of (2S, 4R)-4-[18F]fluoroglutamine and its applications in cancer imaging and treatment response monitoring
(Institute of Cancer Research (University Of London), 2021-01-31)
Glutaminolysis is a crucial pathway to provide the nitrogen source in addition to the carbon source from the glycolysis pathway for proliferating cells. (2S, 4R)-4-[18F]fluoroglutamine (4-[18F]fluoroglutamine) is potentially ...